Pharming Group (NASDAQ:PHAR) Trading 6.1% Higher – What’s Next?

Pharming Group (NASDAQ:PHAR) shares traded up 6.1% on Tuesday . The company traded as high as $10.29 and last traded at $10.29. 2,621 shares were traded during trading, a decline of 50% from the average session volume of 5,281 shares. The stock had previously closed at $9.70.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on PHAR shares. HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, December 17th. Oppenheimer cut their price target on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Finally, Jefferies Financial Group started coverage on Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price objective for the company.

Pharming Group Stock Up 6.1 %

The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $698.02 million, a PE ratio of -39.58 and a beta of 0.05. The company’s 50 day moving average is $8.49 and its two-hundred day moving average is $8.21.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in shares of Pharming Group (NASDAQ:PHAR) by 75.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.